Genprex, INC

Genprex, Inc. announces a strategic agreement with a CDMO to scale up manufacturing for its diabetes gene therapy program, moving towards clinical trials.

Genprex, Inc. has been formally notified that it has regained compliance with the Nasdaq Capital Market's Minimum Bid Price Requirement.

Genprex, Inc. announces a collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in non-small cell lung cancer clinical trials.

Genprex, Inc. has received an exception from the Nasdaq Hearings Panel to continue listing on The Nasdaq Capital Market, subject to specific bid price requirements through December 7, 2026.

Genprex, Inc. files an 8-K detailing a 1-for-22 reverse stock split effective July 16, 2026, and provides updates on its Acclaim-1 and Acclaim-3 clinical trials.

Genprex, Inc. announced that its stockholders approved an amended and restated equity incentive plan and elected directors at the 2026 Annual Meeting.

Genprex, Inc. reports on its Q2 2026 progress, highlighting advancements in its oncology and diabetes gene therapy programs, while addressing ongoing liquidity concerns and Nasdaq compliance.

Genprex reports on progress in its oncology and diabetes gene therapy programs, with increased cash reserves from equity financings and ongoing clinical trial enrollment.

Genprex, a clinical-stage gene therapy company, reported a reduced net loss in Q3 2025 but faces significant liquidity challenges, Nasdaq listing compliance issues, and continues to raise capital through equity offerings.

Genprex, Inc. reports reduced net losses but faces significant financial challenges including a going concern warning, Nasdaq delisting threat, and limited cash runway through August 2025.

Genprex, Inc. reports its Q1 2025 financial results, highlighting ongoing clinical trials for REQORSA and efforts to secure additional funding amidst going concern uncertainties.

Genprex, Inc. reports a net loss of $4.3 million for the third quarter of 2024, while focusing on its key clinical trials and strategic alternatives.

Genprex, Inc. files its 10-K, reporting a net loss for 2024 and providing updates on its clinical development programs in oncology and diabetes.

Genprex, Inc.'s annual report details advancements in its oncology and diabetes gene therapy programs, along with recent financial activities including a reverse stock split and registered direct offering.

Director Brent Longnecker sold a total of 18 shares of Genprex, Inc. common stock for tax purposes.

Genprex's Chief Medical Officer, Mark Stanley Berger, reported a disposition of 7,168 common shares for tax obligations related to RSU vesting.

Genprex, Inc. President, CEO, and CFO Ryan M. Confer disposed of 9,330 shares of common stock on February 27, 2026, to cover tax withholdings from RSU vesting.

Genprex, Inc. Director Jose Antonio Moreno Toscano received 9,000 Restricted Stock Units, with vesting contingent on service, following a 1-for-50 reverse stock split.

Genprex's Chief Medical Officer, Mark Stanley Berger, was granted 28,500 Restricted Stock Units, vesting over two years.

Genprex, Inc. CEO Ryan Confer received an award of 45,000 Restricted Stock Units under the company's equity incentive plan, vesting over two years.

Genprex, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to address key corporate matters including director elections, auditor ratification, executive compensation, and a proposed reverse stock split.

Genprex, Inc. reports significant progress in its oncology and diabetes gene therapy programs, including clinical trial advancements and intellectual property expansion, with key milestones expected in 2026.

Genprex, Inc. is calling its 2025 Annual Meeting of Stockholders to vote on critical proposals including a reverse stock split to regain Nasdaq compliance, an equity incentive plan amendment, and approval for a significant common stock issuance to Lincoln Park Capital Fund, LLC.

Genprex, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Genprex, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, to vote on director election, auditor ratification, executive compensation, and say-on-pay frequency.

Genprex, a clinical-stage gene therapy company, filed an S-1/A to register 1.28 million shares for resale by selling stockholders, while detailing progress in its oncology and diabetes programs and recent financing activities.

Genprex, a clinical-stage gene therapy company, filed an S-1 to register 1.28 million common shares for resale by selling stockholders, while also providing updates on its oncology and diabetes programs and recent financing activities.

Genprex, a clinical-stage gene therapy company, filed an S-1 to register 25 million common shares for resale by Lincoln Park Capital Fund, LLC, while facing Nasdaq delisting for bid price and equity non-compliance.

Genprex, a clinical-stage gene therapy company, has entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $12.5 million in common stock, while advancing its oncology and diabetes programs and addressing Nasdaq listing requirements.

Genprex aims to raise capital through a public offering of common stock, pre-funded warrants, and accompanying warrants, with proceeds intended for working capital and general corporate purposes.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed a Schedule 13G reporting a 2.69% beneficial ownership stake in Genprex, Inc. through warrant holdings.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.72% beneficial ownership stake in Genprex, Inc. through warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Genprex, Inc. common stock as of November 3, 2025.

Forsakringsaktiebolaget Avanza Pension has filed a Schedule 13G, reporting beneficial ownership of 0.0230% of Genprex Inc.'s common stock as of December 31, 2024.